Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: +0.01% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 4 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| CCM | $633M | — | — | 9.6× | -82.8% | 5.6% | -20.2% | 4.4% | -11.7% | -18.3× | 4 |
Peers = companies sharing CCM's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65.9M 100.0% | $384.0M 100.0% | $537.4M 100.0% | $472.1M 100.0% | $485.6M 100.0% | $223.0M 100.0% | $198.4M 100.0% | $190.9M 100.0% | $331.0M 100.0% | $455.0M 100.0% |
| Cost of Revenue | $62.2M 94.4% | $463.1M 120.6% | $614.0M 114.3% | $624.5M 132.3% | $542.5M 111.7% | $209.9M 94.1% | $214.2M 108.0% | $171.1M 89.6% | $233.0M 70.4% | $286.5M 63.0% |
| Gross Profit | $3.7M 5.6% | -$79.2M -20.6% | -$76.6M -14.3% | -$152.4M -32.3% | -$56.9M -11.7% | $13.1M 5.9% | -$15.8M -8.0% | $19.8M 10.4% | $98.0M 29.6% | $168.5M 37.0% |
| Selling, General & Admin | $30.5M 46.2% | $404.4M 105.3% | $330.1M 61.4% | $311.2M 65.9% | $347.7M 71.6% | $294.8M 132.2% | $315.1M 158.9% | $291.9M 152.9% | $237.6M 71.8% | $205.9M 45.3% |
| Operating Income | -$37.4M -56.8% | -$532.2M -138.6% | -$463.0M -86.2% | -$525.0M -111.2% | -$458.3M -94.4% | -$316.0M -141.7% | -$437.3M -220.5% | -$299.2M -156.8% | -$211.9M -64.0% | -$168.6M -37.1% |
| Interest Expense | $21.8M 33.1% | $193.2M 50.3% | $23.3M 4.3% | $120.4M 25.5% | $73.8M 15.2% | $81.4M 36.5% | $28.7M 14.5% | $46.2M 24.2% | $90.0M 27.2% | $89.3M 19.6% |
| Interest & Investment Income | $1.4M 2.1% | $14.0M 3.6% | $10.8M 2.0% | $10.0M 2.1% | $5.9M 1.2% | $8.4M 3.8% | $9.2M 4.6% | $14.2M 7.4% | $12.1M 3.6% | $28.0M 6.1% |
| Other Income (Expense), net | -$1.1M -1.7% | -$9.3M -2.4% | -$10.8M -2.0% | -$216.6M -45.9% | -$1.2M -0.3% | $6.3M 2.8% | $37.1M 18.7% | $34.2M 17.9% | $2.9M 0.9% | $18.2M 4.0% |
| Pretax Income | -$53.4M -81.1% | -$669.6M -174.4% | -$555.6M -103.4% | -$839.9M -177.9% | $529.2M 109.0% | $441.7M 198.0% | $391.1M 197.2% | $225.2M 118.0% | $253.9M 76.7% | $204.6M 45.0% |
| Income Tax Expense | $867K 1.3% | -$17.5M -4.6% | -$24.6M -4.6% | -$70.9M -15.0% | -$6.6M -1.4% | -$37.6M -16.9% | -$39.0M -19.7% | $34.1M 17.8% | $31.8M 9.6% | $60.5M 13.3% |
| Net Income | -$13.3M -20.2% | -$308.2M -80.3% | -$297.7M -55.4% | -$489.7M -103.7% | -$271.4M -55.9% | -$310.0M -139.0% | -$307.0M -154.8% | -$234.9M -123.0% | -$284.3M -85.9% | -$261.9M -57.5% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.10 | $-2.35 | $-2.27 | $-3.74 | $-6.26 | $-5.11 | — | — | — | $-0.29 |
| EPS (Diluted) | $-0.10 | $-2.35 | $-2.27 | $-3.74 | $-6.26 | $-5.11 | — | — | — | $-0.29 |
| Weighted Avg Shares (Basic) | 131.1M | 131.1M | 131.1M | 131.1M | 131.1M | 131.1M | — | — | — | 130.6M |
| Weighted Avg Shares (Diluted) | 131.1M | 131.1M | 131.1M | 131.1M | 131.1M | 131.1M | — | — | — | 130.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$37M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: -12%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $43M covers the $40M due within a year 1.1× over. Scheduled principal only (excludes interest & revolver draws). As of 2014-12-31 (20-F).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~5.3% on $414M of debt.
Cash of $43M is below short-term debt of $140M — relies on refinancing/operations.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-08-05
No standout strengths flagged.
Nothing notable to watch.
Where each multiple sits in its own 14-yr range · 50th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Low operating leverage — profit tracks sales closely (stable, less cyclical).
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 89.6 | 108.0 | 94.1 | 111.7 | 132.3 | 114.3 | 120.6 | 94.4 |
| Gross Profit | 10.4 | -8.0 | 5.9 | -11.7 | -32.3 | -14.3 | -20.6 | 5.6 |
| SG&A | 152.9 | 158.9 | 132.2 | 71.6 | 65.9 | 61.4 | 105.3 | 46.2 |
| Operating Income | -156.8 | -220.5 | -141.7 | -94.4 | -111.2 | -86.2 | -138.6 | -56.8 |
| Income Tax | 17.8 | -19.7 | -16.9 | -1.4 | -15.0 | -4.6 | -4.6 | 1.3 |
| Net Income | -123.0 | -154.8 | -139.0 | -55.9 | -103.7 | -55.4 | -80.3 | -20.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CCM: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.